Clinical Trial

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-09-04; most recent amendment 2026-07-14.
Trial Details
NCT Number NCT07164469
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Bellicum Pharmaceuticals
Conditions Large B-cell Lymphoma, Hodgkin Lymphoma
Enrollment 100 participants
Start Date 2026-12-28
Primary Completion 2031-09-30 (estimated)
Study Completion 2033-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15